Barclays Raises Johnson & Johnson (JNJ) Price Target on Strong Pharma Momentum

Johnson & Johnson (NYSE:JNJ) is included among the 10 Healthcare Stocks with Highest Dividends.

Barclays Raises Johnson & Johnson (JNJ) Price Target on Strong Pharma Momentum

On April 15, Barclays analyst Matt Miksic raised the firm’s price recommendation on Johnson & Johnson (NYSE:JNJ) to $255 from $234. It reiterated an Equal Weight rating on the shares. The analyst noted that the company’s pharma unit delivered its sixth consecutive quarter of double-digit organic growth. In a research note, Barclays said it expects J&J’s new products, along with “durable” core growth in medical technology and pharma, to support its goal of double-digit sales growth by the end of the decade.

During the Q1 2026 earnings call, CEO and Chairman Joaquin Duato said the company delivered operational sales growth of 6.4%. He explained that the company’s growth strategy remains focused on oncology, immunology, neuroscience, cardiovascular, surgery, and vision. He also said the company now has 28 platforms or products generating at least $1 billion in annual revenue and is on track to reach its 2026 target of $100 billion in annual revenue for the first time.

Speaking about oncology, Duato said DARZALEX continues to serve as the gold standard in multiple myeloma, with sales of $4 billion and operational sales growth of 18%. He also pointed to the FDA approval of TECVAYLI in combination with DARZALEX FASPRO, noting that the regimen could position itself as a potential new standard of care as early as the second-line setting.

Johnson & Johnson (NYSE:JNJ) and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The company operates through two segments: Innovative Medicine and MedTech.

While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 14 Value Stocks with Highest Dividends and Early Retirement Portfolio: Top 15 Stocks to Buy

Disclosure: None. Follow Insider Monkey on Google News.